Lipoprotein(a) - Link between Atherogenesis and Thrombosis

Area of Science:

• Cardiovascular biology
• Molecular medicine
• Lipidology

Background:

• Lipoprotein(a) (Lp(a)) is an independent risk factor for cardiovascular disease (CVD).
• Elevated Lp(a) levels (> 200 mg/l) significantly increase CVD risk.
• Lp(a) levels are resistant to conventional lipid-lowering treatments, with plasma apheresis being the primary intervention.

Purpose of the Study:

• To elucidate the cellular effects and molecular mechanisms of Lp(a) in cardiovascular pathology.
• To identify therapeutic targets for mitigating Lp(a)-mediated vascular damage.
• To understand Lp(a)'s role in atherogenesis, thrombogenesis, and inflammation.

Main Methods:

• Review of existing literature on Lp(a) structure and function.
• Analysis of molecular interactions between Lp(a) and vascular components.
• Summary of cellular pathways implicated in Lp(a)-driven cardiovascular disease.

Main Results:

• Lp(a) comprises an LDL/apoB-100 core and an apolipoprotein(a) (Apo(a)) component.
• Both core and Apo(a) interact with coagulation and inflammatory pathways.
• Lp(a) influences vascular cells, including smooth muscle and endothelial cells.

Conclusions:

• Lp(a) actively participates in atherogenesis, thrombogenesis, and inflammation.
• Targeting Lp(a)'s cellular effects is essential for novel therapeutic strategies.
• Further research into Lp(a) molecular pathways can lead to effective CVD treatments.